Citadel Advisors’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,372
| Closed | -$10.2K | – | 13620 |
|
|
2025
Q2 | $10.2K | Buy |
1,372
+720
| +110% | +$6.33K | ﹤0.01% | 12199 |
|
|
2025
Q1 | $5.61K | Sell |
652
-1,184
| -64% | -$18.3K | ﹤0.01% | 13806 |
|
|
2024
Q4 | $65.6K | Buy |
1,836
+748
| +69% | +$38.7K | ﹤0.01% | 12064 |
|
|
2024
Q3 | $51.4K | Buy |
1,088
+80
| +8% | +$3.53K | ﹤0.01% | 11878 |
|
|
2024
Q2 | $50.7K | Buy |
1,008
+180
| +22% | +$13K | ﹤0.01% | 11745 |
|
|
2024
Q1 | $92.7K | Sell |
828
-868
| -51% | -$86.3K | ﹤0.01% | 11461 |
|
|
2023
Q4 | $98.4K | Sell |
1,696
-2,544
| -60% | -$102K | ﹤0.01% | 10954 |
|
|
2023
Q3 | $135K | Sell |
4,240
-2,200
| -34% | -$105K | ﹤0.01% | 10518 |
|
|
2023
Q2 | $530K | Buy |
6,440
+6,008
| +1,391% | +$879K | ﹤0.01% | 7815 |
|
|
2023
Q1 | $44.4K | Buy |
432
+272
| +170% | +$38.2K | ﹤0.01% | 12315 |
|
|
2022
Q4 | $23.4K | Buy |
+160
| New | +$27K | ﹤0.01% | 13014 |
|
|
2022
Q2 | – | Sell |
-424
| Closed | -$42K | – | 13655 |
|
|
2022
Q1 | $42K | Buy |
+424
| New | +$49.5K | ﹤0.01% | 12907 |
|
|
2021
Q4 | – | Sell |
-568
| Closed | -$134K | – | 14403 |
|
|
2021
Q3 | $134K | Buy |
+568
| New | +$166K | ﹤0.01% | 12505 |
|
|
2021
Q2 | – | Sell |
-1,096
| Closed | -$443K | – | 14119 |
|
|
2021
Q1 | $443K | Buy |
+1,096
| New | +$532K | ﹤0.01% | 9950 |
|
|
2020
Q4 | – | Sell |
-1,140
| Closed | -$531K | – | 11291 |
|
|
2020
Q3 | $531K | Buy |
1,140
+556
| +95% | +$281K | ﹤0.01% | 7188 |
|
|
2020
Q2 | $342K | Buy |
+584
| New | +$199K | ﹤0.01% | 7699 |
|
Other funds holding MRSN
Citadel Advisors's MRSN Position: Q1 2026 in Review
Citadel Advisors sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 22,493 shares — an estimated $651K sold.
Citadel Advisors first reported a position in MRSN in Q2 2017 and held it in 27 quarters. The position peaked at $52M in Q4 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Citadel Advisors reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 22,493 Mersana Therapeutics shares in Q1 2026, an estimated $651K.
- Citadel Advisors first reported a position in Mersana Therapeutics in Q2 2017 and held it in 27 quarters.
- Citadel Advisors's Mersana Therapeutics position peaked at $52M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.